Loading
companiesCompany
Tradewind BioScience
Tradewind is developing a single antibody for ovarian cancer that both attacks the tumour cells directly and helps the immune system attack them too.
Overview
Tradewind BioScience is a small San Francisco biotech whose lead candidate is a multi-functional therapeutic antibody for ovarian and other metastatic cancers, designed to bind primary cancer cells directly while enabling natural anti-tumour immunity through the same molecule. The company describes its work as translating insights about metastasis into antibody therapeutics. Programmes are preclinical as far as public sources show; no clinical trial registration or financing details were found in a primary source at the time of checking.
Headquarters
San Francisco, CA, US
Funding
All startupsStartupYC W18
Investors
Type
Stage
Startup · Y Combinator Winter 2018
Website
Similar pages
- CompanyAOA Dx
Shares Y Combinator, Ovarian cancer and the tag yc.
- CompanyAluna
Shares Y Combinator and the tag yc.
- CompanyMednet (theMednet)
Shares Y Combinator and the tag yc.
- CompanyAlixia
Shares Y Combinator and the tag yc.
- CompanyVelorum Therapeutics
Shares Y Combinator and the tag yc.
- CompanyDelee
Shares Y Combinator and the tag yc.
- CompanyResistanceBio (Viosera Therapeutics)
Shares Y Combinator and the tag yc.
- CompanySerinus Biosciences
Shares Y Combinator and the tag yc.